Abstract:Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030. Observations Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic (50%-55%) disease at diagnosis. A multidisciplinary management approach is recommended. Localized pancreas cancer includes resectable, borderline resectable (localized and involving major vascular structures), and locally advanced (unresectable) disease based on the degree of arterial and venous involvement by tumor, typically of the superior mesenteric vessels. For patients with resectable disease at presentation (10%-15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with an anticipated median overall survival of 54.4 months, compared with 35 months for single-agent gemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48-0.86]; P = .003). Neoadjuvant systemic therapy with or without radiation followed by evaluation for surgery is an accepted treatment approach for resectable and borderline resectable disease. For patients with locally advanced and unresectable disease due to extensive vascular involvement, systemic therapy followed by radiation is an option for definitive locoregional disease control. For patients with advanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have a survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to 7% of patients with a BRCA pathogenic germline variant and metastatic PDAC, olaparib, a poly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that improves progression-free survival following initial platinum-based therapy. Conclusions and Relevance Approximately 60 000 new cases of PDAC are diagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease are modestly effective. For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended.

Epidemiology of Pancreatic Cancer: New Version, New Vision

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

Pancreatic cancer: A review of epidemiology, trend, and risk factors

Rising Trends in Pancreatic Cancer Incidence and Mortality in 2000-2014

Advances In The Epidemiology Of Pancreatic Cancer: Trends, Risk Factors, Screening, And Prognosis

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

An Overview of Pancreatic Cancer Diagnosis and Treatment in China: Current Landscape and Future Prospects

Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study

Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019

Recent Advances in Basic Research, Clinical Diagnosis and Treatment of Pancreatic Cancer in 2015

Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible?

Worldwide Burden Of, Risk Factors For, and Trends in Pancreatic Cancer.

Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China

Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening

Current status on epidemiology and management of pancreatic cancer

Pancreatic Cancer: A Review.

A Review of Pancreatic Cancer: Epidemiology, Genetics, Screening, and Management

Correction: the Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009

Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options